Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.

The researchers reported that COVID-induced telogen effluvium can occur after both severe and mild infections, potentially presenting earlier than other causes, and necessitates specific patient management due to its psychological impact.

This study in Saudi Arabia found that 59.70% of participants experienced hair shedding during or after COVID-19, with significant risk factors including being female, having a history of telogen effluvium, and receiving COVID-19 antiviral treatment.

This consensus paper reviews expert opinions on treating telogen effluvium but reports no new clinical findings.

This study suggests that elevated levels of certain heavy metals, rather than zinc, may play a causative role in primary chronic telogen effluvium.

This study evaluated a new topical regenerative treatment and found it can safely and effectively reduce hair loss in patients with androgenetic alopecia and telogen effluvium by mimicking the effects of autologous platelet-rich plasma.

This study shows that Covid-19 infection significantly impacts the emergence of new-onset hair diseases, with a notable association reported between having Covid-19 and developing hair issues.

This study found that lower serum ferritin levels were significantly associated with telogen effluvium compared to healthy subjects and may serve as a potential biomarker for its diagnosis.

COVID-19 can cause different types of hair loss, and proper diagnosis by a specialist may be needed.

This study found that iontophoresis combined with growth factors improved hair density and reduced hair loss in patients with androgenetic alopecia and telogen effluvium, with no serious side effects reported.

This study demonstrated that a mouse model of telogen effluvium induced by lipopolysaccharide was effective for evaluating the therapeutic effects of topical minoxidil, which accelerated hair regrowth in treated mice.

This study found that 72% of patients who recovered from COVID-19 during the second wave reported experiencing significant hair loss, characteristic of telogen effluvium.

This systematic review found a significant association between hair loss and mental health disorders such as major depressive disorder and anxiety, but it was unable to specify correlations for each type of hair loss.

This study by Kyung et al. found a significant association between SARS-CoV-2 infection and an increased risk of developing alopecia areata in long COVID patients, with COVID-19 severity and vaccination status impacting this risk.

This retrospective study of 500 female patients with telogen effluvium found that those with hypothyroidism had more severe hair loss compared to those with normal thyroid function or hyperthyroidism, highlighting the importance of thyroid function testing in these cases.

This review discusses the increased incidence of hair loss and telogen effluvium among COVID-19 patients and evaluates existing evidence for regenerative treatments like PRP and HFSCs, finding limited published data.

This study found no statistical difference in thiol-disulfide balance between telogen effluvium patients and controls, suggesting oxidative stress may not affect telogen effluvium through this mechanism.

This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.

This case report describes a 17-year-old girl with telogen effluvium and severe hair loss following a suspected COVID-19 infection and a history of similar episodes since childhood.

In this descriptive hospital-based study, researchers found that telogen effluvium was the most common cause of hair loss among women aged 20 to 40, with most cases occurring over 6 weeks to 6 months without an associated illness.

In this observational study, researchers found that women with telogen effluvium who had higher baseline ferritin levels or received higher doses and longer durations of iron supplementation reported greater satisfaction, suggesting that iron supplementation can improve patient satisfaction regardless of initial ferritin levels.

This essay discusses telogen effluvium, the issues surrounding its diagnosis and differentiation from other forms of hair loss, and emphasizes the need for empathetic patient care; it reports no new clinical findings.

This study observed that many female pattern hair loss patients had concurrent conditions such as telogen effluvium, hypothyroidism, and hypertension, with a significant percentage having low Vitamin D levels.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This study found that using autologous micrografts from scalp tissues significantly improved hair thickness and density in patients experiencing telogen effluvium following COVID-19, with notable improvements observed over a 6-month follow-up period.

This review found that telogen effluvium was the most common new-onset skin disease after COVID-19 infection, usually resolving spontaneously without medication.

This study found that increased atypical club hair observed in microscopic hair examinations may be characteristic of telogen effluvium compared to healthy individuals and diffuse alopecia areata patients.

In this study, researchers found that women with telogen effluvium had lower MCV/RDW ratios, MPV, and ferritin levels compared to healthy controls, suggesting iron deficiency's involvement in this chronic hair loss condition.

This study reported that over half of recovered COVID-19 patients in Saudi Arabia experienced hair loss, with factors such as high fever, female gender, and prior hair loss significantly associated with incidence of acute telogen effluvium.

In this descriptive cross-sectional study conducted at a Karachi hospital, researchers found a high prevalence of Telogen Effluvium in female COVID-19 survivors, particularly those with diabetes, and noted that dietary supplementation may be linked to reduced hair loss severity post-infection.